drugset / Trial / NCT01376310
GSK1120212 Rollover Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
Timeline
- Start
- 2010-11-02
- Primary completion
- 2018-01-18
- Completion
- 2018-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trametinib | Small molecule | 2 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Erlotinib | Small molecule | — | — |
| Background | Everolimus | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |